← Eichor
Study identifier: NCT06007222 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial

Condition: Aortic Stenosis · TAVI(Transcatheter Aortic Valve Implantation) · Aspirin  ·  Sponsor: OCEAN-SHD Study Group

PhasePhase 4
Planned participants400
Who can joinAll sexes, 20 Years to no upper limit
Healthy volunteersNo

About this study

Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period. Non-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.

This description comes directly from the study's public registry record.

Talk to the study team

Yosuke Sawa  ·  +81-70-2492-4466  ·  sawa.yosuke872@eps.co.jp

Always discuss trial participation with your own doctor first.

Locations (1)

Keio University HospitalShinjuku, Tokyo, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06007222